Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zura Bio Limited filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing antibody candidates for autoimmune and inflammatory diseases. Its disclosures include operating and financial results, Regulation FD materials, clinical-program communications, and risk-related context for a multi-asset immunology pipeline led by tibulizumab (ZB-106).
The company’s SEC record also covers proxy governance matters, annual general meeting voting, executive and compensation arrangements, and capital-structure activity involving Class A ordinary shares, pre-funded warrants, underwriting agreements, and related legal opinions. Current reports and proxy materials provide formal disclosure of material events, shareholder matters, and emerging growth company status.
Zura Bio Ltd director Ajay Nirula filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and does not report any insider purchase, sale, acquisition, or disposition transactions in the summarized data.
Zura Bio Limited filed a current report describing a press release about its Phase 2 TibuSURE study of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis. The company will present the study design as a poster at the 9th Systemic Sclerosis World Congress in Athens.
The global, randomized, double-blind, placebo-controlled Phase 2 trial is expected to enroll about 80 adults, treated every four weeks for 24 weeks, followed by a 28‑week open-label extension. The primary endpoint is change in modified Rodnan Skin Score at Week 24, with topline results anticipated in the first half of 2027.
Tibulizumab is an investigational dual-pathway antibody targeting IL-17A and BAFF. Zura highlights that no clinical efficacy or safety data will be presented in the poster; it focuses on study rationale and design only.
Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.
The shares were acquired at $6.25 per share in a registered offering by the company, increasing AI Biotechnology LLC’s direct holdings to 6,552,725 shares. Related entities, including Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, may be deemed beneficial owners through their control structure but each disclaims beneficial ownership beyond any pecuniary interest.
Zura Bio Limited’s major shareholder group updated its ownership disclosure in this Schedule 13D amendment. AI Biotechnology LLC bought 2,000,000 Class A Ordinary Shares on February 26, 2026 at $6.25 per share in a registered offering, funded with capital from affiliated entities.
After this purchase, AI Biotechnology LLC, together with related Access Industries entities and Len Blavatnik, reports beneficial ownership of 19,699,071 Class A Ordinary Shares, or 18.2% of the class. This figure includes 6,552,725 shares held directly and 13,146,346 shares issuable upon exercise of Private Placement Warrants, which are subject to a “Beneficial Ownership Blocker” that generally limits exercises above 9.99%, or up to 19.99% after notice.
Zura Bio Limited filed an amended current report to update two legal exhibits tied to a prior disclosure. Amendment No. 1 replaces in full Exhibit 5.1, the opinion of Ogier (Cayman) LLP, and Exhibit 23.1, Ogier’s consent, which were originally filed with an earlier report. The amendment states that no other portions of the original report are changed, and it lists previously filed items such as the underwriting agreement, form of pre-funded warrant, and related press releases as unchanged exhibits.
Zura Bio Limited entered into an underwriting agreement for a public offering of equity. The company is issuing 18,200,000 Class A ordinary shares at $6.25 per share and pre-funded warrants to purchase 1,800,000 ordinary shares at $6.249 per warrant.
The underwriters received a 30-day option to buy up to an additional 3,000,000 ordinary shares at the public price, and this option was exercised in full. Zura expects net proceeds of approximately $134.6 million after underwriting discounts and expenses, with closing expected on February 26, 2026, subject to customary conditions.
As of December 31, 2025, Zura estimated cash and cash equivalents of about $109.4 million. After the offering, outstanding ordinary shares are stated as 94,875,460, based on 65,018,058 shares outstanding as of September 30, 2025 and additional shares issued to Athanor Capital, assuming no exercise of the pre-funded warrants.
Zura Bio Limited is offering 18,200,000 Class A ordinary shares and pre-funded warrants to purchase 1,800,000 Class A ordinary shares. The offering is being made at a public price of $6.25 per Class A ordinary share and $6.249 per pre-funded warrant, with expected delivery on or about February 26, 2026.
The prospectus supplement states net proceeds to the company of approximately $117.0 million before expenses (or approximately $134.6 million if the underwriters fully exercise a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares). The company also discloses preliminary cash and cash equivalents of approximately $109.4 million as of December 31, 2025, subject to audit. The pre-funded warrants have a nominal exercise price of $0.001, do not expire, and include ownership limitations up to 9.99% (adjustable up to 19.99% with notice).
Zura Bio Ltd director Mark Eisner received a grant of options to acquire 37,812 shares, described as a "Share Option (Right to Buy)" at an exercise price of $0.0000 per share. These options were awarded as a grant or other acquisition.
The option vests in twelve substantially equal monthly installments over a one-year period starting on February 21, 2026. Any remaining unvested portion will vest on the day immediately preceding the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.
Zura Bio Ltd director Mark Eisner filed an initial Form 3 ownership report. This filing identifies him as a director of Zura Bio Ltd but does not list any stock transactions or share amounts. It serves as a baseline disclosure of his status as an insider for future reporting.
Zura Bio Limited is offering Class A ordinary shares and pre-funded warrants in a primary registered offering (preliminary prospectus supplement dated ). The pre-funded warrants have an exercise price of $0.001 and do not expire; they are exercisable subject to ownership limits (default 9.99%, adjustable to 19.99% with notice).
The company’s Class A ordinary shares trade on Nasdaq under “ZURA”; the last reported sale price on February 23, 2026 was $6.53. The prospectus discloses a preliminary cash and cash equivalents estimate of $109.4 million as of December 31, 2025 (unaudited). The share count basis used is 65,018,058 Class A ordinary shares outstanding as of September 30, 2025.
Proceeds are intended for working capital, advancing the pipeline and general corporate purposes. The offering is subject to completion of terms, underwriting arrangements, and customary conditions; information on offering size, price per share and aggregate proceeds is omitted in the provided excerpt.